ArticleFrontiers in cardiovascular medicine2025
Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis.Cardiovascular diabetology. Endocrinology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Purpose: Sodium glucose co-transporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardioprotective effects in people with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). In this patient group, there is treatment equipoise, from the standpoint of cardiovascular effect between these medication classes; however, factors associated with prescribing are poorly characterized. Methods: We performed a retrospective real-world analysis by creating an electronic health record registry of people with type 2 diabetes and ASCVD (without additional indications for a specific cardioprotective class) who received a prescription for either an SGLT2i or GLP-1RA. We analyzed patient-, provider-, and clinical encounter-related predictors of being prescribed an SGLT2i or GLP-1RA using univariable and multivariable logistic regression analysis. Results: A total of 573 eligible patients received either SGLT2i ( Conclusion: Prescriber's specialty strongly determined the selection of cardioprotective agents. Treatment guidelines should provide more specific guidance regarding patient selection and consider the holistic benefits of each drug class beyond their cardiovascular protective effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.